Search Salaries, Companies, Skills and other Resources

Didn't find your job?

Companies

See how salaries can vary from company to company

II-VI Incorporated develops, manufactures, and markets engineered materials, and optoelectronic components and devices worldwide. The company operates in three segments: II-VI Laser Solutions, II-VI Photonics, and II-VI Performance Products. The II-VI Laser Solutions segment offers optical and electro-optical components and materials primarily used in high-power CO2 lasers; fiber-delivered beam delivery systems, and processing tools and direct diode lasers for industrial lasers; direct diode laser modules, sub-systems, and systems; super-hard materials processing laser systems; and compound se... view company details

Fuseproject focuses on industrial design, packaging, graphics, naming, UI and environmental design. view company details

829 Studios is a digital marketing agency that offers branding, UI design, content strategy, SMM and media optimization service to businesses. view company details

Ironhack is a Global Tech School ranked top 2 worldwide. Our mission is to help people transform their careers and join a thriving community of tech professionals that love what they do. We do this through Intensive courses & bootcamps in Web Development, UX/UI Design, Data Analytics & Cybersecurity, as well as Career Week aimed at helping our students to be prepared to look for a job after the course. We are present in 8 countries and have campuses in 9 locations - Madrid, Barcelona, Miami, Paris, Mexico City, Berlin, Amsterdam, Sao Paulo and Lisbon. Ironhack Key Facts: +6,500 alumni (Ironhac... view company details

TSR, Inc. provides contract computer programming services in the New York metropolitan area, New England, and the Mid-Atlantic region. It offers technical computer personnel to supplement the in-house information technology capabilities of its customers in the areas of .net and java application development, android and IOS mobile application platform development, project management, IT security, cloud development and architecture, UI design and development, network infrastructure and support, and database development and administration, as well as provides business analysts. The company primar... view company details

AndPlus is a technology consulting and development firm that helps clients accelerate digital transformation by closing the gap between strategy and execution. Fusing deep technical and business expertise with a custom Agile development process, we help our clients rapidly implement digital transformation strategies that achieve optimal results with less risk. For more than a decade, AndPlus strategists, builders, innovators, engineers, and designers have pushed the boundaries of mobile, web, IoT, firmware, and advanced technologies to create or improve processes and products that deliver meas... view company details

Fuel Cycle is the leading cloud-based experience management platform for supercharging the relationship between humans and brands. Through community, panel, progressive profiling, and a partnership exchange of 30+ end-point solutions, Fuel Cycle offers the only all-in-one ecosystem that combines quantitative and qualitative data to power real-time business decisions across 4 levels of experience: Product Experience, Brand Experience, Customer Experience, and Employee Experience. Fuel Cycle's digital environment features best in class UX and UI, inspiring levels of participant engagement unsurp... view company details

Clarifai is headquartered in New York City and was founded in 2013 by Matthew Zeiler to bring the world's best image recognition technology to market. Our first image recognition systems held the top 5 spots for classifying objects in images in the ImageNet 2013 competition. Since then Clarifai's deep learning systems have improved orders of magnitude in speed, vocabulary size, memory footprint and have expanded beyond images to extract knowledge from all forms of data. Our award winning platform helps organizations and enterprises gain value from their unstructured image, video, and text data... view company details

Emergent Software is a technology solution provider that offers a full set of software-based services from custom software development to ongoing system maintenance & support serving clients from all industries in the Twin Cities metro, greater Minnesota and throughout the country. We are a Certified Microsoft Development Partner with a talented team of full-stack developers, SQL Server DBA's, Graphic & UI Designers, and Project Managers. In addition to software consulting, we also develop commercial software products like Innovative Mentoring Software, a full-featured CRM solution tailored to... view company details

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule t... view company details

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial fo... view company details

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which i... view company details

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent pa... view company details

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that... view company details

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb cli... view company details

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase ... view company details

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002 that completed phase I/II clinical trial in subjects with DMD; phase I clinical trial for treating heart failure; and phase I/II clinical trial in subjects with myocardial infarction. It is also developing CAP-2003 that is in pre-clinical development ... view company details

Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company, develops therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 that is in Phase II clinical trial for the treatment of critical limb ischemia; CLBS14-CMD, which is in Phase II clinical study to treat coronary microvascular dysfunction; and CLBS14-NORDA that is in Phase III clinical trial for treating no-option refractory disabling angina. The company was formerly known as... view company details

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017.... view company details

Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing drugs based on halogenated xanthenes for oncology and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceut... view company details